Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Systemic scleroderma is an autoimmune disease that affects the skin as well as the internal organs such as lungs, muscles, blood vessels, digestive system, or kidneys. When the immune system malfunctions and attacks the body's own tissues and organs, autoimmune disorders occur. Scleroderma is a group of rare diseases that causes the skin and connective tissues to harden and tighten.

Systemic scleroderma is also known as systemic sclerosis as the fibrosis can affect organs other than the skin. Fibrosis is caused by an increase in the production of collagen, a tough protein that normally strengthens and supports connective tissues throughout the body.

There is no medication that can cure or stop the excessive collagen production that is characteristic of scleroderma. A number of medications, however, can help control scleroderma symptoms and prevent complications.

The treatment is dependent on the symptom, which include corticosteroids, immunosuppressant such as methotrexate, medication to aid breathing, light therapy such as ultraviolet A1 phototherapy, and blood pressure medications.

Global Systemic Scleroderma Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 213 million cases and 4.48 million deaths due to coronavirus disease (COVID-19) were reported till August 25, 2021, across the globe.

Impact of COVID-19 on Demand and Supply of Systemic Scleroderma Treatment

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. Patients with autoimmune disorders may be more vulnerable to COVID-19. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global systemic scleroderma treatment market during the forecast period. For instance, according to the article published in the journal ‘Clinical Rheumatology’ in November 2020, a significantly higher prevalence of COVID-19 is observed in a large number of patients with autoimmune systemic diseases in the hospital in Italy compared to the Italian general population, owing to patients' increased susceptibility to COVID-19 infections and aided by high exposure to the virus at medical facilities prior to individual movement restrictions.

 The global systemic scleroderma treatment market is estimated to be valued at US$ 1.51 Bn in 2021, and is expected to exhibit a CAGR of 4.0 % over the forecast period (2021-2028).

Figure 1: Global Systemic Scleroderma Treatment Market Share (%) Analysis, By Drug Class, 2021

Systemic Scleroderma Treatment  | Coherent Market Insights

The increase in cases of autoimmune diseases is the major factor that is expected to drive the growth of global systemic scleroderma treatment market over the forecast period.

The emerging prevalence of autoimmune diseases is expected to drive the growth of the global systemic scleroderma treatment market. For instance, according to the International Autoimmune Institute & Bingham Memorial Center for Functional Medicine, in 2017, 50 million Americans, 80 percent of whom were women, were diagnosed with one or more autoimmune diseases in the U.S. An autoimmune disease affects one in every twelve Americans, or one out of every nine women in the U.S.

request-sample

Systemic Scleroderma Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 1.51 Bn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 4.0% 2028 Value Projection: US$ 1.99 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Immunosuppressant, Phosphodiesterase 5 Inhibitors (PHA), Endothelin Receptor Antagonists, Prostacyclin  Analogues, Calcium Channel Blockers, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.

Growth Drivers:
  • Increasing cases of autoimmune diseases
  • Increasing product launches and approvals
  • Increasing research and development activities by the market players

Research and Development Activities

Increasing number of research and development activities is expected to aid in the growth of the global systemic scleroderma treatment market over the forecast period. For instance, in June 2021, Horizon Therapeutics plc., a company dedicated to researching, developing, and commercializing medicines to meet the critical needs of people affected by rare and rheumatic diseases, launched a phase 2 multicenter trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis, which is still ongoing. HZN-825 is an oral therapy that is intended to prevent the onset of skin fibrosis (scarring) by blocking the lysophosphatidic acid 1 receptor protein (LPAR1) for treatment of systemic sclerosis. The result of the first phase showed that eight weeks of treatment with HZN-825 reduced skin thickness slightly, with a greater effect in normalizing changed expression of lysophosphatidic acid (LPA)-associated genes than a placebo.

Global Systemic Scleroderma Treatment Market – Regional Analysis

On the basis of region, the global systemic scleroderma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global systemic scleroderma treatment market over the forecast period, owing to the new product launches and approvals. For instance, on September 9, 2019, Boehringer Ingelheim, one of the world's largest pharmaceutical companies, announced that the U.S. Food and Drug Administration (FDA) had approved Ofev (nintedanib) as the first and only medicine to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Ofev is also designated as an Orphan Drug, which provides incentives to assist and encourage the development of drugs for rare diseases.

Moreover, due to strategic collaborations between market players and academic institutes, Europe is expected to witness a significant growth in the global systemic scleroderma treatment market over the forecast period. For instance, on December 10, 2019, Servier Laboratories, a private international pharmaceutical company based in France, partnered with the University Of College London (UCL) in a two-year agreement in which Servier would share scientific knowledge and support with two UCL-led research projects. These studies aim to investigate that which pathways are pathologically altered in lupus patients and how systemic sclerosis develops. The teams hope to develop much-needed new drugs and therapeutic approaches to treat the conditions by better understanding the mechanisms underlying each disease.

Figure 2: Global Systemic Scleroderma Treatment Market Value (US$ Bn), by Region, 2021

Systemic Scleroderma Treatment  | Coherent Market Insights

Global Systemic Scleroderma Treatment Market – Competitive Landscape

Major players operating in the global systemic scleroderma treatment market include Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc., Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.

Scleroderma is a rare autoimmune rheumatic and connective tissue disease that causes inflammation of the skin and other parts of the body.

In the early stages of the disease, Systemic Scleroderma may only affect the skin. Symptoms include skin thickening developing around the mouth, nose, fingers, and other bony areas.

Scleroderma can have varying degrees of impact on the function of the heart, lungs, and kidneys. If left untreated, these issues can become life-threatening.

Market Dynamics

Market players are focused on product launches and approvals from regulatory authorities, this could contribute to the growth of the global systemic scleroderma treatment market over the forecast period. For instance, on January 12, 2021, Timber Pharmaceuticals Inc., a U.S.-based biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, confirmed that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation to TMB-003, Timber's locally delivered formulation of sitaxsentan, for the treatment of systemic sclerosis.

Market players are focusing on product approvals from regulatory authorities, which is expected to strengthen their position in the global systemic scleroderma treatment market. For instance, on May 28, 2020, Theraly Fibrosis, a U.S.-based preclinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had given Orphan Drug Designation (ODD) to TLY012 for the treatment of systemic sclerosis. TLY012 is a proprietary version of the recombinant human TRAIL protein with increased potency, stability, and bloodstream half-life. ODD status is granted by the U.S. FDA to medicines which are intended for the treatment, diagnosis, or prevention of rare diseases or disorders affecting fewer than 200,000 people in the U.S.

Market players are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, which is expected to drive the growth of the global systemic scleroderma treatment market. For instance, on April 2, 2020, Horizon Therapeutics PLC, an Ireland-based biopharmaceutical company, paid an upfront payment of US$ 45 million to acquire privately held Curzion Pharmaceuticals Inc., a U.S.-based pharmaceutical company. According to the acquisition, Horizon will get access to Curzion's drug candidate CZN001, renamed HZN-825, for the treatment of diffuse cutaneous systemic sclerosis, a rare, chronic autoimmune disease characterized by fibrosis, or skin thickening, and problems with multiple organs.

Key features of the study:

  • This report provides an in-depth analysis of global systemic scleroderma treatment market, provides market size (US$ Billion), and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global systemic scleroderma treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global systemic scleroderma treatment market.

Detailed Segmentation:

  • Global Systemic Scleroderma Treatment Market, By Drug Class:
    • Immunosuppressant
    • Phosphodiesterase 5 Inhibitors (PHA)
    • Endothelin Receptor Antagonists
    • Prostacyclin Analogues
    • Calcium Channel Blockers
    • Others
  • Global Systemic Scleroderma Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Systemic Scleroderma Treatment Market, By Region:
    • North America
      • By Drug Class:
        • Immunosuppressant
        • Phosphodiesterase 5 Inhibitors
        • Endothelin Receptor Antagonists
        • Prostacyclin Analogues
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Immunosuppressant
        • Phosphodiesterase 5 Inhibitors
        • Endothelin Receptor Antagonists
        • Prostacyclin Analogues
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Immunosuppressant
        • Phosphodiesterase 5 Inhibitors
        • Endothelin Receptor Antagonists
        • Prostacyclin Analogues
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Immunosuppressant
        • Phosphodiesterase 5 Inhibitors
        • Endothelin Receptor Antagonists
        • Prostacyclin Analogues
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Immunosuppressant
        • Phosphodiesterase 5 Inhibitors
        • Endothelin Receptor Antagonists
        • Prostacyclin Analogues
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Immunosuppressant
        • Phosphodiesterase 5 Inhibitors
        • Endothelin Receptor Antagonists
        • Prostacyclin Analogues
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Boehringer Ingelheim International GmbH *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Pfizer Inc.
    • Bayer AG
    • GlaxoSmithKline plc.
    • Novartis AG
    • Gilead Sciences Inc.
    • United Therapeutics
    • Hoffmann La Roche Ltd.
    • Eli Lilly and Co.
    • Teva Pharmaceutical Industries Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Porter’s Analysis
    • Industry Trends
    • Key Highlights
    • Epidemiology
    • Reimbursement Scenario
    • Regulatory Scenario
    • Product Launch and Approvals
    • Acquisition and Collaboration Scenario
  4.  Global Systemic Scleroderma Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of COVID-19 on Demand and Supply of Systemic Scleroderma Treatment
    • Impact of COVID-19 on the overall Healthcare Sector
  5. Global Systemic Scleroderma Treatment Market, By Drug Class , 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Immunosuppressant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Phosphodiesterase 5 Inhibitors (PHA)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Endothelin Receptor Antagonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Prostacyclin Analogues
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Calcium Channel Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Systemic Scleroderma Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global Systemic Scleroderma Treatment Market, By Region, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
      • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Bn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • Boehringer Ingelheim International GmbH*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
      • Bayer AG
      • GlaxoSmithKline plc
      • Novartis AG
      • Gilead Sciences, Inc.
      • United Therapeutics
      • Hoffmann La Roche Ltd.
      • Eli Lilly and Co.
      • Teva Pharmaceutical Industries Ltd.

*Key pointers provided are also applicable to other companies covered in the scope of the report.

  • Analyst Views
  1. Section
    • Research Methodology
    • About us
    • Contact

*Browse 33 market data tables and 25 figures on “Systemic Scleroderma Treatment Market” - Global Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The market is expected to exhibit a CAGR of 4.0% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 1.51 Bn in 2021.
Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd. are some of the prominent players operating in the market.
The market is expected to be valued at US$ 1.99 Bn in 2028.
North America is the prominent region in the market.
Increasing cases of auto immune diseases, increasing research and development activities, and increasing product launches by the market players are some of the driving factors, which are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.